Development of extramusculoskeletal manifestations in upadacitinib-treated patients with psoriatic arthritis or axial spondyloarthritis
Arthritis Rheumatol 2025;77:536–46 doi: 10.1111/1756-185X.70212
Poddubnyy et al. identified no apparent increase in the risk of developing extramusculoskeletal manifestations (EMMs) in patients with PsA, r-axSpA, and nr-axSpA receiving 15mg UPA in the SELECT trials. Majority of patients did not report a history of EMMs at baseline, regardless of disease indication or study treatment.
In r-axSpA patients, uveitis was numerically lower in patients treated with UPA 15mg vs placebo, and a history of uveitis appeared to predispose patients for future uveitis flares regardless of treatment. A better understanding of the impact of UPA across EMMs in SpA may help guide future treatment recommendations to improve patient care.
Keywords:
